Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2020

Open Access 01-12-2020 | Hypertension | Research article

Multi-state analysis of hypertension and mortality: application of semi-Markov model in a longitudinal cohort study

Authors: Azra Ramezankhani, Michael J. Blaha, Mohammad hassan Mirbolouk, Fereidoun Azizi, Farzad Hadaegh

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Login to get access

Abstract

Background

Most previous research has studied the association of hypertension with cardiovascular disease (CVD) and all-cause mortality by focusing on the transition from the initial state to a single outcome. We investigated the impact of hypertension, defined according to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) (new) and the Seventh Report of the Joint National Committee (JNC7) (old), on CVD death and all-cause mortality considering non-fatal CVD as an intermediate event between two CVD-free and mortality states.

Methods

A total of 3002 Iranian population (47.4% men), aged ≥50 years were followed from 1999 to 2014. Two multi-state semi-Markov models with three transitions were defined for CVD death and all-cause mortality as two outcomes. The multivariable Cox model was used to estimate the effect of hypertension on transition hazards. The mean of 15-year life expectancy of participants in each transition was estimated using the restricted mean survival time.

Results

The ACC/AHA guideline increased the prevalence of hypertension from 43.3 to 68.6%. Among CVD-free individuals, hypertension was significantly associated with increased risk of non-fatal CVD [Hazard Ratio, 1.52 (1.28–1.81) and 1.48 (1.21–1.80)], CVD death [2.96 (2.06–4.25) and 1.98 (1.30–3.04)] and all-cause mortality [1.64 (1.32–2.05) and 1.31 (1.01–1.69)] according the old and new guidelines, respectively. However, after incident non-fatal CVD, the association between hypertension and mortality events was not significant according to both definitions. Hypertensive participants experienced a first non-fatal CVD about 0.9 and 0.6 years earlier than normotensive population according to JNC7 and the 2017 ACC/AHA guidelines, respectively.

Conclusion

Hypertension, according to JNC7 and the ACC/AHA guidelines, significantly increased the risk of mortality events among CVD-free population although the risk was attenuated using ACC/AHA guideline. Hypertension also decreased the number of years lived without CVD and early onset of CVD, and consequently, an increase in the time spent with these diseases. After non-fatal CVD, hypertension had no significant impact on mortality risk according to both guidelines.
Literature
1.
go back to reference O’Doherty MG, Cairns K, O’Neill V, et al. Effect of major lifestyle risk factors, independent and jointly, on life expectancy with and without cardiovascular disease: results from the consortium on health and ageing network of cohorts in Europe and the United States (CHANCES). Eur J Epidemiol. 2016;31(5):455–68.PubMedPubMedCentralCrossRef O’Doherty MG, Cairns K, O’Neill V, et al. Effect of major lifestyle risk factors, independent and jointly, on life expectancy with and without cardiovascular disease: results from the consortium on health and ageing network of cohorts in Europe and the United States (CHANCES). Eur J Epidemiol. 2016;31(5):455–68.PubMedPubMedCentralCrossRef
2.
go back to reference Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2(7):775-81. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2(7):775-81.
3.
go back to reference Lotfaliany M, Akbarpour S, Mozafary A, et al. Hypertension phenotypes and incident cardiovascular disease and mortality events in a decade follow-up of a Middle East cohort. J Hypertens. 2015;33(6):1153–61.PubMedCrossRef Lotfaliany M, Akbarpour S, Mozafary A, et al. Hypertension phenotypes and incident cardiovascular disease and mortality events in a decade follow-up of a Middle East cohort. J Hypertens. 2015;33(6):1153–61.PubMedCrossRef
4.
go back to reference Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.PubMedCrossRef Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.PubMedCrossRef
5.
go back to reference Vega G, Martínez S, Jiménez PA, et al. Effect of cardiovascular risk factors on long-term morbidity and mortality following acute myocardial infarction. Rev Esp Cardiol. (English Edition. 2007;60(7):703–13.PubMedCrossRef Vega G, Martínez S, Jiménez PA, et al. Effect of cardiovascular risk factors on long-term morbidity and mortality following acute myocardial infarction. Rev Esp Cardiol. (English Edition. 2007;60(7):703–13.PubMedCrossRef
6.
go back to reference Zornoff LA, Paiva SA, Assalin VM, et al. Clinical profile, predictors of mortality, and treatment of patients after myocardial infarction, in an academic medical center hospital. Arq Bras Cardiol. 2002;78(4):401–5.CrossRef Zornoff LA, Paiva SA, Assalin VM, et al. Clinical profile, predictors of mortality, and treatment of patients after myocardial infarction, in an academic medical center hospital. Arq Bras Cardiol. 2002;78(4):401–5.CrossRef
7.
go back to reference Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res. 2002;11(2):91–115.PubMedCrossRef Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res. 2002;11(2):91–115.PubMedCrossRef
8.
go back to reference Meira-Machado L, de Uña-Álvarez J, Cadarso-Suárez C, et al. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009;18(2):195–222.PubMedCrossRef Meira-Machado L, de Uña-Álvarez J, Cadarso-Suárez C, et al. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009;18(2):195–222.PubMedCrossRef
9.
go back to reference Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389–430.PubMedCrossRef Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389–430.PubMedCrossRef
10.
go back to reference Gasperoni F, Ieva F, Barbati G, et al. Multi-state modelling of heart failure care path: a population-based investigation from Italy. PLoS One. 2017;12(6):e0179176.PubMedPubMedCentralCrossRef Gasperoni F, Ieva F, Barbati G, et al. Multi-state modelling of heart failure care path: a population-based investigation from Italy. PLoS One. 2017;12(6):e0179176.PubMedPubMedCentralCrossRef
11.
go back to reference Ramezankhani A, Azizi F, Hadaegh F, et al. Diabetes and number of years of life lost with and without cardiovascular disease: a multi-state homogeneous semi-Markov model. Acta Diabetol. 2018;55(3):253-62. Ramezankhani A, Azizi F, Hadaegh F, et al. Diabetes and number of years of life lost with and without cardiovascular disease: a multi-state homogeneous semi-Markov model. Acta Diabetol. 2018;55(3):253-62.
12.
go back to reference Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248.
13.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.PubMedCrossRef
14.
go back to reference Azizi F, Ghanbarian A, Momenan AA, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials. 2009;10(1):5.PubMedPubMedCentralCrossRef Azizi F, Ghanbarian A, Momenan AA, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials. 2009;10(1):5.PubMedPubMedCentralCrossRef
15.
go back to reference Sardarinia M, Akbarpour S, Lotfaliany M, et al. Risk factors for incidence of cardiovascular diseases and all-cause mortality in a middle eastern population over a decade follow-up: Tehran lipid and glucose study. PLoS One. 2016;11(12):e0167623.PubMedPubMedCentralCrossRef Sardarinia M, Akbarpour S, Lotfaliany M, et al. Risk factors for incidence of cardiovascular diseases and all-cause mortality in a middle eastern population over a decade follow-up: Tehran lipid and glucose study. PLoS One. 2016;11(12):e0167623.PubMedPubMedCentralCrossRef
16.
go back to reference Association AD. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Supplement 1):S14–80.CrossRef Association AD. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Supplement 1):S14–80.CrossRef
17.
go back to reference Khalili D, Azizi F, Asgari S, et al. Outcomes of a longitudinal population-based Cohort Study and pragmatic community trial: Findings from 20 years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84748. Khalili D, Azizi F, Asgari S, et al. Outcomes of a longitudinal population-based Cohort Study and pragmatic community trial: Findings from 20 years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84748.
18.
go back to reference Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1-67. Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1-67.
20.
go back to reference Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30(19):2409–21.PubMedCrossRef Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30(19):2409–21.PubMedCrossRef
21.
go back to reference Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72(1):215–21.PubMedCrossRef Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72(1):215–21.PubMedCrossRef
22.
go back to reference Klein JP, Gerster M, Andersen PK, et al. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Prog Biomed. 2008;89(3):289–300.CrossRef Klein JP, Gerster M, Andersen PK, et al. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Prog Biomed. 2008;89(3):289–300.CrossRef
23.
go back to reference De Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non-and semi-parametric multi-state and competing risks models. Comput Methods Prog Biomed. 2010;99(3):261–74.CrossRef De Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non-and semi-parametric multi-state and competing risks models. Comput Methods Prog Biomed. 2010;99(3):261–74.CrossRef
24.
go back to reference Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.PubMedCrossRef Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.PubMedCrossRef
25.
go back to reference Oh J-Y, Allison MA, Barrett-Connor E. Different impacts of hypertension and diabetes mellitus on all-cause and cardiovascular mortality in community-dwelling older adults: the rancho Bernardo study. J Hypertens. 2017;35(1):55–62.PubMedCrossRef Oh J-Y, Allison MA, Barrett-Connor E. Different impacts of hypertension and diabetes mellitus on all-cause and cardiovascular mortality in community-dwelling older adults: the rancho Bernardo study. J Hypertens. 2017;35(1):55–62.PubMedCrossRef
26.
go back to reference Ikeda A, Iso H, Yamagishi K, et al. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC study. Am J Hypertens. 2009;22(3):273–80.PubMedCrossRef Ikeda A, Iso H, Yamagishi K, et al. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC study. Am J Hypertens. 2009;22(3):273–80.PubMedCrossRef
27.
go back to reference Collaboration PS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.CrossRef Collaboration PS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.CrossRef
28.
go back to reference Glümer C, Carstensen B, Sandbæk A, et al. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004;27(3):727–33.PubMedCrossRef Glümer C, Carstensen B, Sandbæk A, et al. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004;27(3):727–33.PubMedCrossRef
29.
go back to reference Khera R, Lu Y, Lu J, et al. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. bmj. 2018;362:k2357.PubMedPubMedCentralCrossRef Khera R, Lu Y, Lu J, et al. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. bmj. 2018;362:k2357.PubMedPubMedCentralCrossRef
30.
go back to reference Lee JH, Kim S-H, Kang S-H, et al. Blood pressure control and cardiovascular outcomes: real-world implications of the 2017 ACC/AHA hypertension guideline. Sci Rep. 2018;8(1):1–8. Lee JH, Kim S-H, Kang S-H, et al. Blood pressure control and cardiovascular outcomes: real-world implications of the 2017 ACC/AHA hypertension guideline. Sci Rep. 2018;8(1):1–8.
31.
go back to reference Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol. 2018;71(2):109–18.PubMedCrossRef Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol. 2018;71(2):109–18.PubMedCrossRef
32.
go back to reference Franco OH, Peeters A, Bonneux L, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women. Hypertension. 2005;46(2):280–6.PubMedCrossRef Franco OH, Peeters A, Bonneux L, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women. Hypertension. 2005;46(2):280–6.PubMedCrossRef
33.
go back to reference Maessen MF, Eijsvogels TM, Hijmans-Kersten BT, et al. Vascular function and structure in veteran athletes after myocardial infarction. Med Sci Sports Exerc. 2017;49(1):21–8.PubMedCrossRef Maessen MF, Eijsvogels TM, Hijmans-Kersten BT, et al. Vascular function and structure in veteran athletes after myocardial infarction. Med Sci Sports Exerc. 2017;49(1):21–8.PubMedCrossRef
34.
go back to reference Borghi C, Omboni S, Reggiardo G, et al. Efficacy of Zofenopril compared with placebo and other angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction and previous cardiovascular risk factors: a pooled individual data analysis of 4 randomized, double-blind, controlled, Prospective Studies. J Cardiovasc Pharmacol. 2017;69(1):48.PubMedPubMedCentralCrossRef Borghi C, Omboni S, Reggiardo G, et al. Efficacy of Zofenopril compared with placebo and other angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction and previous cardiovascular risk factors: a pooled individual data analysis of 4 randomized, double-blind, controlled, Prospective Studies. J Cardiovasc Pharmacol. 2017;69(1):48.PubMedPubMedCentralCrossRef
35.
go back to reference Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-29. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-29.
36.
go back to reference Jia H, Zack MM, Thompson WW. The effects of diabetes, hypertension, asthma, heart disease, and stroke on quality-adjusted life expectancy. Value Health. 2013;16(1):140–7.PubMedCrossRef Jia H, Zack MM, Thompson WW. The effects of diabetes, hypertension, asthma, heart disease, and stroke on quality-adjusted life expectancy. Value Health. 2013;16(1):140–7.PubMedCrossRef
37.
go back to reference Turin TC, Murakami Y, Miura K, et al. Hypertension and life expectancy among Japanese: NIPPON DATA 80. Hypertension Res. 2012;35(9):954–8.CrossRef Turin TC, Murakami Y, Miura K, et al. Hypertension and life expectancy among Japanese: NIPPON DATA 80. Hypertension Res. 2012;35(9):954–8.CrossRef
38.
go back to reference Turk-Adawi K, Sarrafzadegan N, Fadhil I, et al. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nat Rev Cardiol. 2018;15(2):106-19. Turk-Adawi K, Sarrafzadegan N, Fadhil I, et al. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nat Rev Cardiol. 2018;15(2):106-19.
39.
go back to reference Antonelli L, Katz M, Bacal F, et al. Heart failure with preserved left ventricular ejection fraction in patients with acute myocardial infarction. Arq Bras Cardiol. 2015;105(2):145–50.PubMedPubMedCentral Antonelli L, Katz M, Bacal F, et al. Heart failure with preserved left ventricular ejection fraction in patients with acute myocardial infarction. Arq Bras Cardiol. 2015;105(2):145–50.PubMedPubMedCentral
40.
go back to reference Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it “ok” to discontinue? Curr Cardiol Rev. 2012;8(1):77–84.PubMedPubMedCentralCrossRef Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it “ok” to discontinue? Curr Cardiol Rev. 2012;8(1):77–84.PubMedPubMedCentralCrossRef
41.
go back to reference Esteghamati A, Abbasi M, Alikhani S, et al. Prevalence, awareness, treatment, and risk factors associated with hypertension in the Iranian population: the national survey of risk factors for noncommunicable diseases of Iran. Am J Hypertens. 2008;21(6):620–6.PubMedCrossRef Esteghamati A, Abbasi M, Alikhani S, et al. Prevalence, awareness, treatment, and risk factors associated with hypertension in the Iranian population: the national survey of risk factors for noncommunicable diseases of Iran. Am J Hypertens. 2008;21(6):620–6.PubMedCrossRef
42.
43.
go back to reference Ramezankhani A, Azizi F, Hadaegh F, et al. Sex-specific clustering of metabolic risk factors and their association with incident cardiovascular diseases: a population-based prospective study. Atherosclerosis. 2017;263:249–56.PubMedCrossRef Ramezankhani A, Azizi F, Hadaegh F, et al. Sex-specific clustering of metabolic risk factors and their association with incident cardiovascular diseases: a population-based prospective study. Atherosclerosis. 2017;263:249–56.PubMedCrossRef
Metadata
Title
Multi-state analysis of hypertension and mortality: application of semi-Markov model in a longitudinal cohort study
Authors
Azra Ramezankhani
Michael J. Blaha
Mohammad hassan Mirbolouk
Fereidoun Azizi
Farzad Hadaegh
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01599-7

Other articles of this Issue 1/2020

BMC Cardiovascular Disorders 1/2020 Go to the issue